HAPPY EASTER! 50% Off Premium Subscription Claim Offer ⏰ 0d 00h 00m 00s

Capricor Therapeutics Earnings Calls

Q1 2025 (Upcoming)
Release date May 12, 2025
EPS estimate -$0.330
EPS actual -
Revenue estimate 3.158M
Revenue actual -
Expected change +/- 9.27%
Q4 2024 Beat
-$0.160 (48.39%)
Release date Mar 19, 2025
EPS estimate -$0.310
EPS actual -$0.160
EPS Surprise 48.39%
Revenue estimate 5.5M
Revenue actual 11.131M
Revenue Surprise 102.37%
Q3 2024 Missed
-$0.380 (-11.76%)
Release date Nov 13, 2024
EPS estimate -$0.340
EPS actual -$0.380
EPS Surprise -11.76%
Revenue estimate 9.87M
Revenue actual 2.262M
Revenue Surprise -77.09%
Q2 2024 Missed
-$0.350 (-9.37%)
Release date Aug 07, 2024
EPS estimate -$0.320
EPS actual -$0.350
EPS Surprise -9.37%
Revenue estimate 3.58M
Revenue actual 3.971M
Revenue Surprise 10.93%

Last 4 Quarters for Capricor Therapeutics

Below you can see how CAPR performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Missed
Release date Aug 07, 2024
Fiscal end date Jun 30, 2024
Price on release $3.56
EPS estimate -$0.320
EPS actual -$0.350
EPS surprise -9.37%
Date Price
Aug 01, 2024 $3.91
Aug 02, 2024 $3.89
Aug 05, 2024 $3.77
Aug 06, 2024 $3.91
Aug 07, 2024 $3.56
Aug 08, 2024 $3.88
Aug 09, 2024 $3.76
Aug 12, 2024 $3.92
Aug 13, 2024 $3.93
4 days before -8.95%
4 days after 10.39%
On release day 8.99%
Change in period 0.512%
Q3 2024 Missed
Release date Nov 13, 2024
Fiscal end date Sep 30, 2024
Price on release $16.91
EPS estimate -$0.340
EPS actual -$0.380
EPS surprise -11.76%
Date Price
Nov 07, 2024 $18.85
Nov 08, 2024 $19.70
Nov 11, 2024 $19.54
Nov 12, 2024 $18.10
Nov 13, 2024 $16.91
Nov 14, 2024 $18.49
Nov 15, 2024 $18.61
Nov 18, 2024 $18.38
Nov 19, 2024 $18.46
4 days before -10.29%
4 days after 9.17%
On release day 9.34%
Change in period -2.07%
Q4 2024 Beat
Release date Mar 19, 2025
Fiscal end date Dec 31, 2024
Price on release $12.22
EPS estimate -$0.310
EPS actual -$0.160
EPS surprise 48.39%
Date Price
Mar 13, 2025 $12.79
Mar 14, 2025 $13.23
Mar 17, 2025 $12.88
Mar 18, 2025 $11.61
Mar 19, 2025 $12.22
Mar 20, 2025 $14.36
Mar 21, 2025 $12.86
Mar 24, 2025 $13.28
Mar 25, 2025 $13.48
4 days before -4.46%
4 days after 10.31%
On release day 17.51%
Change in period 5.39%
Q1 2025 (Upcoming)
Release date May 12, 2025
Fiscal end date Mar 30, 2025
Price on release -
EPS estimate -$0.330
EPS actual -
Date Price
Apr 11, 2025 $9.29
Apr 14, 2025 $9.40
Apr 15, 2025 $9.82
Apr 16, 2025 $9.64
Apr 17, 2025 $11.25

Capricor Therapeutics Earnings Call Transcript Summary of Q4 2024

Recent Developments:

  • The FDA accepted Capricor's Biologics License Application (BLA) for deramiocel targeting DMD cardiomyopathy with a priority review status; the target PDUFA date is August 31, 2025.
  • A pre-licensing inspection of Capricor's manufacturing facility is scheduled for Q2 2025.
  • The company has successfully completed over 700 infusions of deramiocel in clinical trials, showing a strong safety profile and clinically significant efficacy in treating DMD cardiomyopathy.

Commercialization Strategy:

  • Capricor is preparing for deramiocel's U.S. launch alongside its commercial partner NS Pharma, who has a dedicated team for market access and reimbursement strategies.
  • Feedback from payers indicates a favorable outlook for reimbursement, given the lack of approved therapies for DMD cardiomyopathy.
  • Approximately 50-60% of the DMD population in the U.S. (about 7,500 patients) could be eligible for treatment if approved.

Financial Position:

  • Capricor's cash balance stands at approximately $150 million, expected to support operations into 2027 without further financing.
  • An additional $80 million milestone payment from Nippon Shinyaku is anticipated upon FDA approval, plus a potential priority review voucher, adding significant non-dilutive cash resources to the company's balance sheet.

Manufacturing Capacity:

  • Current GMP-compliant facilities can support 250-500 patients per year.
  • Plans to expand to a new facility (25,000 square feet) are underway, set to increase capacity to 2,000-3,000 patients per year by mid-2026.

Pipeline and Future Directions:

  • Capricor is exploring opportunities for label extensions into skeletal muscle myopathy for Becker muscular dystrophy (BMD) and evaluating additional indications for deramiocel in other orphan cardiomyopathies.
  • The company is also developing an exosome platform (StealthX) aimed at drug delivery, currently involved in a vaccine program focused on COVID-19.

Considerations for Investors:

  • Approval timelines and successful commercialization are critical; investors should watch for updates around the August 2025 PDUFA date.
  • Financial stability is bolstered by significant cash reserves, partnerships, and potentially lucrative milestone payments.
  • Market potential remains substantial given the unmet need for DMD cardiomyopathy treatments and a favorable reimbursement outlook.
  • Expansion plans for manufacturing suggest proactive steps to meet demand if deramiocel receives FDA approval.

Capricor is positioned for a transformative year, aiming to shift from a clinical-stage organization to a commercial entity with successful product launches.

Capricor Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for CAPR?
Capricor Therapeutics (CAPR) has scheduled its earnings report for May 12, 2025 before the markets open.

What is the CAPR price-to-earnings (P/E) ratio?
CAPR P/E ratio as of Apr 17, 2025 (TTM) is -10.60.

What is the CAPR EPS forecast?
The forecasted EPS (Earnings Per Share) for Capricor Therapeutics (CAPR) for the first fiscal quarter 2025 is -$0.330.

What are Capricor Therapeutics's retained earnings?
On its balance sheet, Capricor Therapeutics reported retained earnings of $11.13 million for the latest quarter ending Dec 31, 2024.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT CAPRICOR THERAPEUTICS
Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Ph...
GOLDEN STAR
Ticker Change Signal Date
I
ISTB
$48.08
0.291% Apr 14
B
BSCS
$20.24
0.395% Apr 14
BAH
$108.78
2.31% Apr 11
K
$82.14
0.183% Apr 10
ESGR
$332.23
0.226% Apr 10

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE